Therapy
    Mechanism of Action
    Sponsor
    Phase
    Completion Date
    Number of CALS Sites
    Lithium Chloride
    Multiple
    Investigator Initiated
    2/3
    2011
    15
    Ceftriaxone
    Excitotoxicity
    Investigator Initiated
    3
    2011
    8
    Dexpramipexole
    Mitochondria
    Biogen Idec
    3
    2012
    6
    Tirasemtiv
    Muscle
    Cytokinetics
    2
    2014
    12
    Ozanezumab
    Axon/ Neuromuscular Junction
    GlaxoSmithKline
    2
    2017
    5
    Tirasemtiv
    Muscle
    Cytokinetics
    3
    2017
    10
    NP001
    Inflammation
    Neuraltus Pharmaceuticals, Inc.
    2
    2017
    1
    Acthar Gel
    Inflammation
    Mallinckrodt
    2/3
    2019
    5
    Reldesemtiv
    Muscle
    Cytokinetics
    2
    2019
    9
    GDC-0134
    Axon Degeneration
    Genentech, Inc.
    1
    2020
    1
    Levosimendan
    Muscle
    Orion
    3
    2020
    9
    Ravulizumab
    Inflammation
    Alexion
    3
    2021
    7
    Tofersen (BIIB067)
    SOD1 Antisense Oligonucleotide (ASO)
    Biogen/Ionis
    1/2/3
    2021
    4
    Pimozide
    Neuromuscular Junction
    Investigator Initiated
    2
    2021
    9
    Tegoprubart (AT-1501)
    Inflammation
    Eledon Pharmaceuticals
    2
    2022
    1
    BIIB078
    Antioxidant
    Biogen/Ionis
    1
    2022
    4
    Withania Somnifera
    Inflammation
    Investigator Initiated
    2
    2022
    1
    WVE-004
    Antioxidant
    Wave Therapeutics
    1/2
    2023
    2
    Enoxacin
    miRNA
    Investigator Initiated
    1/2
    2023
    1
    MR-Guided FUS
    Blood Brain Barrier
    Investigator Initiated
    1
    2022
    1
    ABBV-CLS-7262
    EIF2b Activation
    Calico Life Sciences LLC
    1
    2023
    7
    AP-101
    SOD1 Antibody
    AL-S Pharma
    2
    2023
    4
    ANX005
    C1q inhibitor
    Annexon, Inc.
    2
    2023
    5
    Oral Edaravone
    Antioxidant
    Mitsubishi Tanabe Pharma Development America, Inc.
    3
    2023
    10
    ION363
    FUS Antisense Oligonucleotide (ASO)
    Ionis
    3
    2024
    1
    Ibudilast
    Inflammation
    MediciNova
    3
    2024
    6
    Reldesemtiv
    Muscle
    Cytokinetics
    3
    2024
    11
    SAR443820
    RIPK1 Inhibitor
    Sanofi
    2
    2025
    5
    BIIB105
    Ataxin 2 Antisense Oligonucleotide (ASO)
    Biogen/Ionis
    1
    2026
    1
    Tofersen (Presymptomatic)
    SOD1 Antisense Oligonucleotide (ASO)
    Biogen/Ionis
    3
    2027
    2
    QRL-201
    STATHMIN-2 Antisense Oligonucleotide (ASO)
    QurAlis Corporation
    1
    2025
    4
    PrimeC
    Inflammation
    NeuroSense Therapeutics Ltd.
    2
    2024
    1
    Repetitive TMS
    Excitotoxicity
    Investigator Initiated
    Open-label, pilot
    2026
    1
    VRG50635
    RIPK1 Inhibitor
    Verge Genomics
    1
    2026
    2
    PROBIO_HA114
    Mitochondria
    Investigator Initiated
    2
    2027
    1
    Darifenacin
    Neuromuscular Junction
    Investigator Initiated
    2
    2026
    2
    Dazucorilant
    Inflammation
    Corcept Therapeutics
    2
    2027
    2
    LY4256984
    UNC13A Antisense Oligonucleotide (ASO)
    Eli Lilly and Company
    1
    2027
    5
    Pridopidine
    Sigma‑1 receptor agonist
    Prilenia
    3
    2029
    3
    Prosetin
    MAP4K inhibitor
    ProJenX
    1
    2026
    1
    NB-4746
    Axon Degeneration
    Nura Bio
    1/2
    2028
    3
    VHB937
    Inflammation
    Novartis Pharmaceuticals
    2
    2028
    4
    Usnoflast
    Inflammation
    Zydus
    2
    2028
    2
    Focused Ultrasound
    Blood Brain Barrier
    Sunnybrook Health Sciences Centre
    1
    2027
    1
    COYA 302
    Inflammation
    Coya Therapeutics
    2
    2027
    4
    AMX0114
    CAPN2 Antisense Oligonucleotide (ASO)
    Amylyx Pharmaceuticals Inc.
    1
    2027
    5
    ALN-SOD
    SOD1 siRNA
    Regeneron
    1/2
    2031
    5
    ARGX-119
    Neuromuscular Junction
    argenx
    2
    2026
    2